Literature DB >> 31544536

Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis.

Eli Muchtar1, Angela Dispenzieri1, Dragan Jevremovic2, David Dingli1, Francis K Buadi1, Martha Q Lacy1, Wilson Gonsalves1, Rahma Warsame1, Taxiarchis V Kourelis1, Suzanne R Hayman1, Prashant Kapoor1, Nelson Leung1,3, Stephen Russell1, John A Lust1, Yi Lin1, Ronald S Go1, Steven Zeldenrust1, Robert A Kyle1, S Vincent Rajkumar1, Shaji K Kumar1, Morie A Gertz1.   

Abstract

Response assessment in light chain (AL) amyloidosis is challenging given the low level of circulating free light chains usually seen. Multi-parametric flow cytometry (MFC) from a marrow aspirate was demonstrated to retain a prognostic significance in several recent studies. In this work, 82 AL patients who had MFC study at end of therapy were analysed based on whether clonal plasma cells were detected or not. Among patients who achieved deep response (i.e. very good partial response or complete response) to first-line therapy, lack of clonal marrow plasma cells as measured by MFC was associated with improved progression-free survival (PFS) compared to patients with residual clonal plasma cells (3-year PFS 88% vs. 46%, p = .003), particularly among patients who achieved a complete response (3-year PFS 100% vs. 33%, p = .001). Absence of clonal plasma cells by MFC compared with patients with detectable clonal plasma cells among deep responders was associated with lower level of involved light chain (involved free light chain (iFLC), median 1.1 vs. 1.7 mg/dL; p = .02) and higher frequency of renal response (100% vs. 68%; p = .005). Further studies are needed to determine if MFC should be incorporated into response criteria in AL amyloidosis.

Entities:  

Keywords:  Flow cytometry; light chain; minimal residual disease; response; survival

Year:  2019        PMID: 31544536     DOI: 10.1080/13506129.2019.1666709

Source DB:  PubMed          Journal:  Amyloid        ISSN: 1350-6129            Impact factor:   7.141


  10 in total

1.  Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis.

Authors:  Surbhi Sidana; Eli Muchtar; M Hasib Sidiqi; Dragan Jevremovic; Angela Dispenzieri; Wilson Gonsalves; Francis Buadi; Martha Q Lacy; Suzanne R Hayman; Taxiarchis Kourelis; Prashant Kapoor; Ronald S Go; Rahma Warsame; Nelson Leung; S Vincent Rajkumar; Robert A Kyle; Morie A Gertz; Shaji K Kumar
Journal:  Am J Hematol       Date:  2020-02-14       Impact factor: 10.047

2.  Assessment of minimal residual disease using multiparametric flow cytometry in patients with AL amyloidosis.

Authors:  Andrew Staron; Eric J Burks; John C Lee; Shayna Sarosiek; J Mark Sloan; Vaishali Sanchorawala
Journal:  Blood Adv       Date:  2020-03-10

3.  Clinical value of minimal residual disease assessed by multiparameter flow cytometry in amyloid light chain amyloidosis.

Authors:  Xiaozhe Li; Beihui Huang; Junru Liu; Meilan Chen; Jingli Gu; Juan Li
Journal:  J Cancer Res Clin Oncol       Date:  2021-05-08       Impact factor: 4.553

4.  Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis.

Authors:  Giovanni Palladini; Bruno Paiva; Ashutosh Wechalekar; Margherita Massa; Paolo Milani; Marta Lasa; Sriram Ravichandran; Isabel Krsnik; Marco Basset; Leire Burgos; Mario Nuvolone; Ramón Lecumberri; Andrea Foli; Noemi Puig; Melania Antonietta Sesta; Margherita Bozzola; Pasquale Cascino; Alice Nevone; Jessica Ripepi; Pierpaolo Berti; Simona Casarini; Ombretta Annibali; Alberto Orfao; Jesus San-Miguel; Giampaolo Merlini
Journal:  Blood Cancer J       Date:  2021-02-16       Impact factor: 11.037

Review 5.  Biomarkers in AL Amyloidosis.

Authors:  Despina Fotiou; Foteini Theodorakakou; Efstathios Kastritis
Journal:  Int J Mol Sci       Date:  2021-10-09       Impact factor: 5.923

Review 6.  Light Chain Amyloidosis: Epidemiology, Staging, and Prognostication.

Authors:  Kelty R Baker
Journal:  Methodist Debakey Cardiovasc J       Date:  2022-03-14

7.  Light Chain Stabilization: A Therapeutic Approach to Ameliorate AL Amyloidosis.

Authors:  Gareth J Morgan; Joel N Buxbaum; Jeffery W Kelly
Journal:  Hemato       Date:  2021-10-05

8.  Detection of minimal residual disease by next generation sequencing in AL amyloidosis.

Authors:  Shayna Sarosiek; Cindy Varga; Allison Jacob; Maria Teresa Fulciniti; Nikhil Munshi; Vaishali Sanchorawala
Journal:  Blood Cancer J       Date:  2021-06-21       Impact factor: 11.037

Review 9.  Future Perspectives.

Authors:  Angela Dispenzieri; Giampaolo Merlini
Journal:  Hematol Oncol Clin North Am       Date:  2020-12       Impact factor: 3.722

10.  Comparing measures of hematologic response after high-dose melphalan and stem cell transplantation in AL amyloidosis.

Authors:  Shayna Sarosiek; Luke Zheng; J Mark Sloan; Karen Quillen; Dina Brauneis; Vaishali Sanchorawala
Journal:  Blood Cancer J       Date:  2020-09-01       Impact factor: 11.037

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.